Researchers have developed a machine learning model called DreaMS, which significantly accelerates the analysis of previously unknown molecules. The study is published in Nature Biotechnology.

Tech oligarchs’ wildest visions of tomorrow amount to a modern secular theology that is both mesmerizing and, in his view, ...

The pharmaceutical and biotech company recently combined its HR and IT departments under a single leader in a move that has ...

AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional ...

Diagens has developed the Rapid AI karyotype total solution based on iMedImage ®, a globally leading general medical imaging ...

From May 24 to 27, 2025, the annual conference of the European Society of Human Genetics (ESHG) 2025 held successfully in Milan, Italy. Hangzhou Diagens ...

The whole genome amplification market is anticipated to reach over USD 6.5 million by 2034, with sales projected to reach USD 2.9 million in 2024. The WGA industry is envisioned to register an 8.1% ...

Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, ...

More importantly, AI can track whether management's previous commitments and projections materialised in subsequent quarters.

Rokeby brings a distinctive perspective to this exploration through his work as director of the University of Toronto’s BMO ...